ANGPTL3 and cardiovascular disorder: Recent studies have shown that inhibiting ANGPTL3 activity can reduce the risk of cardiovascular disease; an optimized LNP (lipid nanoparticle) system has been developed for delivering CRISPR/SpCas9 mRNA and ANGPTL3-targeting guide RNA to liver cells of wild-type C57BL76 to inhibit ANGPTL3 activity and reduce the risk of cardiovascular disease.